Literature DB >> 26748534

An Aromatic Hydroxyamide Attenuates Multiresistant Staphylococcus aureus Toxin Expression.

Jan Vomacka1, Vadim S Korotkov1, Bianca Bauer1, Franziska Weinandy1, Martin H Kunzmann2, Joanna Krysiak2, Oliver Baron3, Thomas Böttcher4, Katrin Lorenz-Baath1, Stephan A Sieber5.   

Abstract

Methicillin-resistant Staphylococcus aureus (MRSA) causes severe infections with only few effective antibiotic therapies currently available. To approach this challenge, chemical entities with a novel and resistance-free mode of action are desperately needed. Here, we introduce a new hydroxyamide compound that effectively reduces the expression of devastating toxins in various S. aureus and MRSA strains. The molecular mechanism was investigated by transcriptome analysis as well as by affinity-based protein profiling. Down-regulation of several pathogenesis associated genes suggested the inhibition of a central virulence-related pathway. Mass spectrometry-based chemical proteomics revealed putative molecular targets. Systemic treatment with the hydroxyamide showed significant reduction of abscess sizes in a MRSA mouse skin infection model. The absence of resistance development in vitro further underlines the finding that targeting virulence could lead to prolonged therapeutic options in comparison to antibiotics that directly address bacterial survival.
© 2016 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

Entities:  

Keywords:  click chemistry; drug discovery; medicinal chemistry; proteomics; toxicology

Mesh:

Substances:

Year:  2016        PMID: 26748534     DOI: 10.1002/chem.201503981

Source DB:  PubMed          Journal:  Chemistry        ISSN: 0947-6539            Impact factor:   5.236


  1 in total

1.  Targeting the endoplasmic reticulum-mitochondria interface sensitizes leukemia cells to cytostatics.

Authors:  Fabian Koczian; Olga Nagło; Jan Vomacka; Binje Vick; Phil Servatius; Themistoklis Zisis; Britta Hettich; Uli Kazmaier; Stephan A Sieber; Irmela Jeremias; Stefan Zahler; Simone Braig
Journal:  Haematologica       Date:  2018-10-11       Impact factor: 9.941

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.